Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305060 | 0.82 | CYP1A2 (0.60) | MAPTKMT2ACYP1A2KCNN4CYP2C19 | |
| SCHEMBL29613223 | 0.82 | CYP1A2 (0.60) | MAPTKMT2ACYP1A2KCNN4CYP2C19 | |
| SCHEMBL16753453 | 0.82 | CYP1A2 (0.60) | MAPTKMT2ACYP1A2KCNN4CYP2C19 | |
| SCHEMBL11715049 | 0.82 | CYP1A2 (0.54) | MAPTKMT2ACYP1A2KCNN4CYP2C19 | |
| SCHEMBL7255208 | 0.80 | CYP1A2 (0.52) | MAPTKMT2ACYP1A2KCNN4CYP2C19 | |
| SCHEMBL11842568 | 0.79 | CYP1A2 (0.70) | MAPTKMT2ACYP1A2KCNN4CYP2C19 | |
| SCHEMBL9710789 | 0.79 | HDAC3 (0.50) | MAPTKMT2ACYP1A2KCNN4CYP2C19 | |
| SCHEMBL4778710 | 0.79 | MAPT (0.59) | MAPTKMT2ACYP1A2KCNN4CYP2C19 | |
| SCHEMBL5552907 | 0.78 | CYP1A2 (0.50) | MAPTKMT2ACYP1A2KCNN4CYP2C19 | |
| SCHEMBL368343 | 0.77 | MAPT (1.00) | MAPTKMT2ACYP1A2KCNN4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5320096-A | — | — | None | — | — | JP | disclosed |
| US-11746178-B2 | Polymer production method and radical polymerization initiating group-containing compound | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2023-09-05 | — | — | US | disclosed |
| US-11746178-B2 | Polymer production method and radical polymerization initiating group-containing compound | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2023-09-05 | — | — | US | disclosed |
| US-10982033-B2 | Polymer production method and radical polymerization initiating group-containing compound | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20190002619-A1 | POLYMER PRODUCTION METHOD AND RADICAL POLYMERIZATION INITIATING GROUP-CONTAINING COMPOUND | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| JP-H05320096-A | PRODUCTION OF GLYCOLLIC ACIDS | NIPPON SYNTHETIC CHEM IND CO LTD:THE | 1993-12-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | MAPT 2414/4885KMT2A 4052/4885CYP1A2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.